Protagen Expands Cooperation with Bayer HealthCare

09-Dec-2011 - Protagen AG and Bayer HealthCare Pharmaceuticals announced the start of a new collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis. This new cooperation project builds on the results of the Endometriosis biomarker discovery study performed last year, and is ...

Protagen and Charles River Form Strategic Partnership

02-Nov-2011 - Protagen AG and Charles River Laboratories International, Inc. are announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range of services. Charles River ...

instrAction and Protagen Form Strategic Alliance

17-Mar-2011 - instrAction GmbH and Protagen AG signed a strategic alliance for the development of customized instrAction® Phases for downstream processing of biotherapeutics.“The instrAction® Phases are proprietary synthetic chromatography phases which show excellent performance compared to commonly used ...

Protagen AG and MicroDiscovery GmbH cooperate in biomarker development

18-Oct-2010 - Dortmund based Protagen AG and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases. „Our proprietary technology platform UNIarray® and MicroDiscovery’s certified software solutions for the ...

Key Patent of Protagen Granted in Japan

13-Aug-2010 - Protagen AG announced that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and ...

Protagen Deepens Cooperation With Bayer Schering Pharma

11-Jun-2010 - Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is ...

Protagen AG Appoints New Board Members

14-Jan-2010 - Protagen AG appoints two new members for the Executive Board. Dr. Peter Schulz-Knappe, former CSO at Proteome Sciences plc., started his new position with the beginning of the year. He will take over operational responsibility for the Business Unit Diagnostics. At the same time, Martin Blüggel, ...

UNIchip protein biochips from Protagen identify significant off-target binding for TNF-alpha inhibitors

Findings could explain side effects seen with these biological drugs for treating rheumatic diseases

02-Apr-2008 - Tumor Necrosis Factor (TNF)- inhibitors used to treat rheumatic diseases may bind to a significant number of proteins other than their main target, according to the results of an in vitro study published in Analytical and Bioanalytical Chemistry. This off-target binding activity might explain ...

Protagen raises EUR 1 million to expand its protein biochips business unit

17-Jan-2008 - Protagen AG announced the closing of an interim financing round. The EUR 1 million raised will be used to expand the company's protein biochips business unit. The capital raised in this round has come from the existing institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and ...

Protagen launches GMP protein analysis services

27-Apr-2007 - Protagen AG has been awarded Good Manufacturing Practice (GMP) certification and has announced that it will be providing customers with protein analysis services in accordance with the international quality assurance guidelines with immediate effect. Protagen is one of the first biotechnology ...